Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
CytoSorbents Corporation specializes in blood purification technologies for critical care, cardiac surgery, and organ transplantation. Its flagship product, CytoSorb, removes inflammatory mediators, toxins, and blood thinners from blood using porous polymer beads. The company develops and markets extracorporeal cartridges and devices globally, targeting high-risk patients with conditions like sepsis, COVID-19, organ failure, and bleeding risks, with a focus on improving clinical outcomes and reducing healthcare costs.
This description was generated via AI from an annual report. Updated about 1 year ago.